COVID-19 and cardiovascular disease

Clin Investig Arterioscler. 2020 Nov-Dec;32(6):263-266. doi: 10.1016/j.arteri.2020.10.005.
[Article in English, Spanish]
No abstract available

Publication types

  • Editorial

MeSH terms

  • Angiotensin-Converting Enzyme 2 / metabolism
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • COVID-19 / complications*
  • COVID-19 / epidemiology
  • COVID-19 Drug Treatment
  • Cardiovascular Diseases / etiology*
  • Cardiovascular Diseases / prevention & control
  • Endothelium, Vascular / physiology
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Pandemics
  • Risk Factors
  • SARS-CoV-2* / physiology
  • Spike Glycoprotein, Coronavirus / metabolism
  • Thrombosis / epidemiology
  • Thrombosis / etiology
  • Toll-Like Receptor 3 / metabolism
  • Virus Internalization

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Spike Glycoprotein, Coronavirus
  • TLR3 protein, human
  • Toll-Like Receptor 3
  • spike protein, SARS-CoV-2
  • Angiotensin-Converting Enzyme 2